These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23192888)

  • 1. Pharmaceutical cocrystals: the coming wave of new drug substances.
    Brittain HG
    J Pharm Sci; 2013 Feb; 102(2):311-7. PubMed ID: 23192888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Cocrystal: An Antique and Multifaceted Approach.
    Panzade PS; Shendarkar GR
    Curr Drug Deliv; 2017; 14(8):1097-1105. PubMed ID: 27758692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical cocrystals: walking the talk.
    Bolla G; Nangia A
    Chem Commun (Camb); 2016 Jun; 52(54):8342-60. PubMed ID: 27278109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced methodologies for cocrystal synthesis.
    Douroumis D; Ross SA; Nokhodchi A
    Adv Drug Deliv Rev; 2017 Aug; 117():178-195. PubMed ID: 28712924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cocrystal and its Application in the Field of Active Pharmaceutical Ingredients and Food Ingredients.
    Wang N; Xie C; Lu H; Guo N; Lou Y; Su W; Hao H
    Curr Pharm Des; 2018; 24(21):2339-2348. PubMed ID: 29788878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
    Greco K; Bogner R
    J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and Quality Control of Pharmaceutical Cocrystals.
    Izutsu KI; Koide T; Takata N; Ikeda Y; Ono M; Inoue M; Fukami T; Yonemochi E
    Chem Pharm Bull (Tokyo); 2016 Oct; 64(10):1421-1430. PubMed ID: 27319284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of the causes of cocrystal dissociation at high humidity.
    Eddleston MD; Thakuria R; Aldous BJ; Jones W
    J Pharm Sci; 2014 Sep; 103(9):2859-2864. PubMed ID: 24481664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
    Newman A; Reutzel-Edens SM; Zografi G
    J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical Cocrystals as an Opportunity to Modify Drug Properties: From the Idea to Application: A Review.
    Sokal A; Pindelska E
    Curr Pharm Des; 2018; 24(13):1357-1365. PubMed ID: 29278209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental cocrystal screening and solution based scale-up cocrystallization methods.
    Malamatari M; Ross SA; Douroumis D; Velaga SP
    Adv Drug Deliv Rev; 2017 Aug; 117():162-177. PubMed ID: 28811184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical cocrystals: an overview.
    Qiao N; Li M; Schlindwein W; Malek N; Davies A; Trappitt G
    Int J Pharm; 2011 Oct; 419(1-2):1-11. PubMed ID: 21827842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical cocrystals and poorly soluble drugs.
    Thakuria R; Delori A; Jones W; Lipert MP; Roy L; Rodríguez-Hornedo N
    Int J Pharm; 2013 Aug; 453(1):101-25. PubMed ID: 23207015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs.
    Bolla G; Sarma B; Nangia AK
    Chem Rev; 2022 Jul; 122(13):11514-11603. PubMed ID: 35642550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical cocrystallization techniques. Advances and challenges.
    Rodrigues M; Baptista B; Lopes JA; Sarraguça MC
    Int J Pharm; 2018 Aug; 547(1-2):404-420. PubMed ID: 29890258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents.
    Almarsson Ö; Peterson ML; Zaworotko M
    Pharm Pat Anal; 2012 Jul; 1(3):313-27. PubMed ID: 24236844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical salts and cocrystals involving amino acids: a brief structural overview of the state-of-art.
    Tilborg A; Norberg B; Wouters J
    Eur J Med Chem; 2014 Mar; 74():411-26. PubMed ID: 24487190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.